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Abstract
Objectives To assess the cost effectiveness of pali-
vizumab for prevention of severe respiratory syncytial
virus (RSV) disease in high-risk infants in Spain, incor-
porating country-specific observational hospitalisation
data.
Methods An existing decision tree model, designed using
data from a large international clinical trial of palivizumab
versus no prophylaxis, was updated to include Spanish
observational hospitalisation data. The analysis was per-
formed for preterm children born at or before 32 weeks
gestational age, who are at high risk of developing severe
RSV disease requiring hospitalisation. Data sources inclu-
ded published literature, official price/tariff lists and
national population statistics. The primary perspective of
the study was that of the Spanish National Health Service
in 2006.
Results The base-case analysis included the direct medi-
cal costs associated with palivizumab prophylaxis and
hospital care for RSV infections. Use of palivizumab pro-
duces an undiscounted incremental cost-effectiveness ratio
(ICER) of €6,142 per quality-adjusted life-year (QALY),
and a discounted ICER of €12,814/QALY.
Conclusion Palivizumab provides a cost-effective
method of prophylaxis against severe RSV disease
requiring hospitalisation among preterm infants in Spain.
Keywords Cost-effectiveness  Model  Respiratory
syncytial virus  Palivizumab  Spain
JEL Classification I18
Background
Respiratory syncytial virus (RSV) is a leading cause of lower
respiratory tract illness in children, the elderly and immu-
nocompromised individuals. Preterm infants and children
with heart and lung problems are particularly at risk of
hospitalisation due to severe RSV disease [1]. Hospitalisa-
tion rates in these high-risk patients may be as high as 20%
[2]. A study by Clarke et al. [3] in the United Kingdom
assessed the rate of RSV hospitalisation in unprophylaxed
children with bronchopulmonary dysplasia (BPD) in Liv-
erpool over two RSV seasons (1998/1999 and 1999/2000) to
be 19.7%. Other estimates of RSV hospitalisation rates in
at-risk children come from studies of the protective effect of
RSV immune globulin intravenous (RSV-IGIV) compared
to no prophylaxis. The results of the first multicentre ran-
domised controlled trial with RSV-IGIV, in children less
than 48 months of age at study entry who suffered under-
lying chronic lung disease (CLD) or congenital heart disease
or a history of preterm birth (\35 weeks gestation) reported
a hospitalisation rate of 20% for the placebo group versus
7% in the children who received prophylaxis [4]. In the
PREVENT study of children with CLD and/or a history of
preterm birth, the incidence of RSV hospitalisation was
13.5% in the placebo group and 8% in those who received
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RSV-IGIV [5]. IMpact, a large multinational clinical trial,
has reported a significant 55% relative reduction (95% CI:
38–72%) in the overall rate of hospitalisations due to RSV
infection in high-risk children given palivizumab compared
with those given placebo [6]. Of the palivizimab group,
4.8% experienced RSV hospitalisation, with the figure for
the placebo group being 10.6% (P = 0.0004). In Spain it has
been estimated that RSV is responsible for 15,000–20,000
emergency visits, 7,000–14,000 hospital admissions, and
70–250 deaths per year [7].
Investigations of the long-term prognosis of patients
hospitalised due to RSV infection in infancy have shown
measurable respiratory abnormalities that may persist for
several years following infection. Among young school
children, previous RSV infection may increase the risk of
asthma tenfold [8]. In a prospective cohort study, 47 chil-
dren who had experienced RSV bronchiolitis severe enough
to warrant hospitalisation at a mean age of 3.5 months were
compared with matched controls. At age 7.5 years, the
cumulative prevalence of asthma was 30% in the RSV
group and 3% in the control group (P \ 0.0001) [8].
In an observational study of 2,415 preterm Canadian
infants hospitalised due to RSV and 20,254 matched con-
trols, those in the RSV cohort were at least eight times
more likely to be hospitalised for respiratory conditions
during the 2-year follow-up period than controls [5]. The
overall mortality rate in these patients was also signifi-
cantly higher than in the control cohort (8.11 vs 1.58%,
P = 0.001), showing a significant risk of mortality beyond
the initial hospitalisation for RSV [9]. By pooling placebo
and intervention subjects from three trials, Joffe et al. [10]
have estimated that the probability of death during the
acute phase of RSV hospitalisation among high-risk infants
is 1.2% (95% confidence interval, 0–2.8%).
As current treatment options for severe RSV infection are
limited to supportive care, the focus has shifted to preven-
tion. Palivizumab, a humanised monoclonal antibody given
once a month as an intramuscular injection during antici-
pated periods of risk, is currently the only product approved
for use for prevention of severe RSV disease in Spain. Pal-
ivizumab is licensed for use in children born at or before
35 weeks gestational age who are less than 6 months old at
the onset of the RSV season, in children less than 2 years old
who have received treatment for BPD within the proceeding
6 months and in children less than 2 years old with hae-
modynamically significant congenital heart disease (CHD)
[11]. This indication was granted on the basis of two large,
multinational, placebo-controlled trials, which reported a
55% reduction in the risk of hospitalisation in preterm/BPD
children and a 45% reduction in the risk of hospitalisation in
children with CHD, compared to no prophylaxis [6, 12].
Furthermore, there is evidence that the benefits of pro-
phylaxis with palivizumab persist beyond the initial period
of infection resulting from long-term morbidity and mor-
tality. Investigations of the long-term prognosis of patients
with RSV disease in infancy have shown measurable
respiratory abnormalities immediately or several years
following infection. Sampalis [9] investigated the mor-
bidity and mortality after RSV-associated hospitalisations
among preterm Canadian infants. This study analysed data
from 2,415 preterm infants [32–35 weeks gestational age
(GA)] hospitalised for proven or probable RSV and 20,254
matched control infants. The patients in both cohorts were
matched with respect to potential confounders. The overall
mortality rate in the RSV cohort in the 2 years after the
initial hospitalisation was 8.11% compared to 1.58% in the
control cohort (P = 0.001), showing a significant risk of
mortality beyond the initial hospitalisation for RSV. The
odds ratios calculated showed that infants with an RSV
hospitalisation were at least eight times more likely to be
hospitalised for respiratory conditions during the follow-up
period and the overall mortality rate in these patients was
also significantly higher compared with the control cohort
(8.11 vs 1.58%, P = 0.001) [7].
Another study showed that early RSV infection predis-
poses children to recurrent wheezing during their early
childhood but that airway morbidity is transient and sub-
sides during school age [13]. Among young school chil-
dren, previous RSV infection may increase the risk of
asthma tenfold [14]. In 140 children aged 7.5 year—47 of
whom were hospitalized for RSV infection and 93 paired
controls—the cumulative prevalence of recurrent wheezing
was 30% in the RSV group and 3% in the control group.
A prospective, controlled study carried out in 27 centres
in Europe, including Spain, showed that significantly fewer
preterm infants in the palivizumab group experienced
recurrent wheezing during a 12-month follow up period
than those who had not received prophylaxis (6.8 vs
19.1%; P \ 0.001), a 64% risk reduction [15]. Children
under 36 months of age who had received palivizumab
during the previous respiratory season were matched by
gestational age (\28 weeks, 28–32 weeks, 33–35 weeks)
and age (±3 months) with children who had never received
palivizumab; fewer children who received prophylactic
treatment with palivizumab required hospitalisation for any
kind of respiratory disease (4.2 vs 7%; P = 0.045).
Data were collected over four seasons, comparing RSV
hospitalisation rates and risk factors in two Spanish cohorts
of at-risk infants. The first cohort comprised 1,583 infants
followed during the 1998–1999 and 1999–2000 RSV sea-
sons, before palivizumab was licensed for use in Spain.
The second cohort comprised 1,919 infants who received
palivizumab prophylaxis for the two subsequent RSV
seasons (2000–2001 and 2001–2002). Both cohorts inclu-
ded infants who were preterm (B32 weeks gestational age)
and were less than 6 months old at start of RSV season, in
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line with Spanish recommendations for the use of pali-
vizumab [7].
The outcomes were validated by comparing data with
IMpact. The palivizimab group experienced RSV hospi-
talisation in 4.8% of cases and the placebo group in 10.6%.
The Spanish data showed that the annual mean RSV hos-
pitalisation rate in the palivizumab cohort was 3.95%
compared with 13.25% in infants who did not receive
prophylaxis [18]. These data show that absolute outcomes
for palivizumab and ‘‘no prophylaxis’’ are similar
(3.95% vs 4.8% (palivizumab) and 10.6% vs 13.25% (no
prophylaxis).
A health economic model has been developed to assess
the cost-effectiveness of palivizumab prophylaxis in high-
risk groups of children, the structure of which has recently
been described for the United Kingdom setting [16]. When
cost effectiveness was assessed from the perspective of the
Spanish healthcare provider using this model, use of
palivizumab produced a discounted incremental cost-
effectiveness ratio (ICER) of €13,849 per quality-adjusted
life-year (QALY), taking into account the direct medical costs
associated with RSV prophylaxis and hospitalisation [17].
While this analysis demonstrates that palivizumab is a
cost-effective treatment for the prevention of severe RSV
disease in high-risk infants, the model has its limitations.
Firstly, the impact of palivizumab use on hospitalisation
was limited to a single RSV season, corresponding to data
available from the IMpact trial in which children were
followed for 150 days from the point of randomisation [6].
However, these 1-year data have limited external validity,
as the majority of children who are at risk in any one
season will also be at risk in the subsequent season or
seasons. Also, in the absence of local data, hospitalisation
rates were taken from the international IMpact trial, further
limiting the external validity of the results for any one
country. This limitation is especially relevant for a pro-
phylaxis model, which is driven by the regional incidence
of RSV infection.
Recent publication of multiple season data for Spain by
Pedraz et al. [18] on behalf of the Infeccion Respiratoria
Infantil por Virus Respiratorio Sincitial (IRIS) Study
Group allows customisation of the existing core model to
more accurately reflect the impact of palivizumab in the
Spanish healthcare setting. Data were collected over four
seasons, comparing RSV hospitalisation rates and risk
factors in two Spanish cohorts of at-risk infants. The first
cohort comprised 1,583 infants followed during the 1998–
1999 and 1999–2000 RSV seasons, before palivizumab
was licensed for use in Spain. The second cohort comprised
1,919 infants who received palivizumab prophylaxis for the
two subsequent RSV seasons (2000–2001 and 2001–2002).
Both cohorts included infants who were preterm
(B32 weeks gestational age) and were less than 6 months
old at start of RSV season, in line with Spanish recom-
mendations for the use of palivizumab [7].
An overall reduction of 70% in the rate of RSV hospi-
talisation was observed in the palivizumab group (3.95 vs
13.25%) despite this group’s lower gestational ages, more
severe neonatal intensive care unit (ICU) respiratory
courses and higher incidence of CLD. Children in the
control group had a higher risk for RSV-related hospitali-
sation than those in the palivizumab group (odds ratio,
3.86; 95% confidence interval, 2.83–5.25) [18]. Data from
this study support the effectiveness of palivizumab in sig-
nificantly reducing RSV-related hospitalisations in high-
risk preterm infants over two respiratory seasons [18].
The objective of the current analysis was to incorporate
the new multiple season data from Pedraz into the existing
core cost-effectiveness model, in order to increase the
validity of the results for the Spanish healthcare setting.
Methods
The model considers the clinical and economic impact of
palivizumab versus no prophylaxis in a hypothetical cohort
of high-risk children, corresponding with those in the IRIS
studies: preterm children born at or before 32 weeks ges-
tational age who were less than 6 months old at the onset of
RSV season. In order to accurately reflect the Spanish
healthcare setting in 2006, the existing decision tree model
was adjusted using hospitalisation data from the IRIS Study
Group, other published literature, official Spanish price/
tariff lists and national population statistics. Clinical events
and utilities, which are not country-specific, were derived
from international studies where no Spanish clinical data
are available [19]. For economic measures and information
on therapeutic choices, country-specific data sources have
been used [19]. The primary perspective was that of the
national health financer, the base-case analysis including
the direct costs associated with use of palivizumab and
those resulting from hospitalisation of children with RSV
infection. The costs of managing possible sequelae caused
by severe RSV infection (recurrent wheezing) were also
considered, as were potential indirect costs due to lost
productivity following the death of a child (societal
perspective).
The base-case analysis assumed a lifetime follow-up
period in order to capture the impact of palivizumab on
long-term morbidity (recurrent wheezing) and mortality
resulting from an RSV infection. The reduction in RSV
hospitalisation resulting from use of palivizumab was
extended in this analysis to 2 years, using observational
data from the IRIS studies. The number of RSV hospi-
talisations from the IRIS studies was extrapolated to
provide an estimate of life-years gained (LYG) and
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utilities incorporated to calculate QALYs by the impact of
RSV hospitalisation on morbidity (recurrent wheezing)
and mortality. The life time impact is also required to
include the costs beyond the RSV hospitalisation period,
which include the medical costs for management of
wheezing and future lost productivity of a child resulting
from mortality.
A discount rate of 3% was applied to both costs and
clinical outcomes in the base-case analysis, as recom-
mended by Spanish guidelines for pharmacoeconomic
analyses [20]. This rate was varied between 0 and 6% in a
sensitivity analysis.
Design
Probabilities and life expectancy
Figure 1 shows the structure of the model. This is identical
to the core decision tree model developed for the UK [16]
and the original Spanish analysis, but the probabilities have
been modified using observational data for Spain [18;
Table 1]. Children may develop an RSV infection leading
to hospitalisation. The majority of these children will be
managed in a paediatric ward, but a proportion will require
transfer to a neonatal or paediatric intensive care unit
(NICU or PICU) [21]. A small proportion of the children
may die. Among the surviving children, a significant pro-
portion may develop long-term sequelae (e.g. wheezing,
asthma). The analysis was based on a comparison of pro-
phylaxis with palivizumab versus no prophylaxis. Details
of the model are also provided in the published study for
the United Kingdom, which was the template (basis) for the
model in Spain [16].
Hospitalisation For both the palivizumab group and
infants not receiving prophylaxis, the rate of hospitalisation
in the base-case analysis was derived from the IRIS studies.
The annual mean RSV hospitalisation rate in the pali-
vizumab cohort was 3.95% (3.9% in the first season and
3.95% in the second), compared with 13.25% (13.4% in the
first season and 13.1% in the second) in infants who did not
receive prophylaxis [18].
Table 1 Clinical probabilities
Preterm (B32 weeks) Probability P value Reference
Palivizumab (%) No prophylaxis (%)
Hospitalisation
1-year 13.40 3.90 \0.001 Pedraz et al. [18]
2-year 13.10 3.95 \0.001
1 and 2 year: cumulative 26.50 7.90 0.001
1 and 2 year: annual mean
Subpopulation
B 28 weeks 5.4 13.0 \0.001
29–32 weeks 2.5 9.9 \0.001
1 and 2 year: cumulative 5.5 19.7 \0.007
1 and 2 year: annual mean
Probability P value Impact trial
Palivizumab (%) No prophylaxis (%)
Hospitalisation
Overall 4.8 10.6 \0.001
Preterm, excluding BPD 1.8 8.1 \0.001
BPD 7.9 12.8 0.038
Probability P value Impact trial
RSV hosp. (%) Control (%)
Mortality
Observational study 8.12 1.58 0.001 Sampalis [9]
Observational study Spain 0.31 1.39 NS Pedraz et al. [18]
Life expectancy (years) 78.05 Official life tables on Spanish statistics
BPD Bronchopulmonary dysplasia
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Mortality Infant mortality is an important consideration
from a clinical and societal perspective as a small reduction
in the rate of mortality in children can lead to a large
increase in life expectancy. The base-case analysis was
based on the overall mortality rates observed in the IRIS
studies: six patients in the palivizumab cohort died (0.31%)
compared with 22 in the no prophylaxis group (1.39%)
[18]. Two scenario analyses were performed. The first
assumed that there was no difference in mortality between
groups, while the second scenario was based on mortality
rates in the 2 years following hospitalisation due to RSV,
observed by Sampalis [9]. The overall mortality rate in the
RSV cohort in the 2 years after the initial hospitalisation
was 8.11% compared to 1.58% in the control cohort
(P = 0.001).
Life expectancy There are no clinical data to suggest a
reduced life expectancy due to childhood RSV infection. It
was therefore assumed that life expectancy after surviving
an RSV episode is similar to life expectancy in the general
population of cohort children at 1 year of age, derived from
official population statistics for Spain [22]. Life expectancy
at birth in Spain is 79.29 years. Consequently, life expec-
tancy at age 1 is approximately 78.29 years.
Utilities
The incorporation of utilities in this model was based on
the study by Greenough et al. which was also used in the
published study for the UK [16]. This study by Greenough
et al. [23] reported utilities in children with a history of
RSV hospitalisation (Table 2). The median health utility
index (HUI) two multi-attribute utility function (HUI2) was
0.88 (range 0.16–1.00) in the RSV proven children, which
was significantly lower (P = 0.0088) than that in the non-
RSV children (median 0.95, range 0.03–1.00). The median
HUI three multi-attribute score (HUI3) of the two groups
did not differ significantly (0.93, range 20.05–1.00 vs 0.97,
range 20.32–1.00). The following assumptions were made
for the model base-case analysis:
• High-risk children who have not been hospitalised for
RSV will not have perfect health, but will have a utility
corresponding to the median HUI2 score for children
without RSV (u = 0.95).
• High-risk children who have been hospitalised for RSV
will have a utility corresponding to the median HUI2
score for children with RSV (u = 0.88).
• This model assumes that, beyond 16 years of age, there
will be no difference in utility between the different
High-risk
infant
palivizumab
no
palivizumab
RSV hospitalisation
including ICU
no RSV 
hospitalisation
RSV hospitalisation
including ICU
no RSV 
hospitalisation
survive
die
survive
die
no sequelae
sequelae
no sequelae
sequelae
Fig. 1 Decision tree model for
infants at high risk of
respiratory syncytial virus
(RSV) infection. ICU Intensive
care unit
Table 2 Utilities for health states
Preterm infants with BPD
Literature RSV proven Non-RSV proven P value
HUI 2 0.88 (0.16–1.00) 0.95 (0.03–1.00) 0.0088
HUI 3 0.93 (–0.05–1.00) 0.97 (–0.32–1.00) NS
Model input RSV hospitalisation No RSV hospitalisation [16 years
Base-case analysis (uses HUI 2 data) 0.88 (0.16–1.00) 0.95 (0.03–1.00) 1
Scenario analysis (uses HUI 3 data) 0.93 (–0.05–1.00) 0.93 (–0.05–1.00) 1
HUI Health utilities index
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high-risk groups, regardless of whether or not they
develop RSV or long-term respiratory morbidity after
an RSV hospitalisation. All patients older than 16 are
assumed to have perfect health (u = 1).
• The median multi-attribute score on the HUI3 did not
differ significantly between the two groups. Thus, a
scenario analysis was performed based on a utility of
0.93 (the utility measured in RSV children in this
study) for all children up to 16 years of age.
Resource use and costs
A range of costs were included in the analysis: costs
associated with the acquisition and administration of pali-
vizumab; costs for RSV hospitalisation and costs for
treating the longer-term consequences of severe RSV
infection, such as recurrent wheezing. All costs were
adjusted for inflation to correspond to the year 2006.
Palivizumab
Palivizumab is available in 50 mg and 100 mg vials with a
mean acquisition cost, provided by Abbott Laboratories in
Spain, of €8.78/mg. The recommended dosage is 15 mg/kg
body weight administered by intramuscular injection once
a month for 4–5 months. It was assumed that a 100 mg vial
would be used in 95% of administrations, whereas a 50 mg
vial would be used for the remaining 5%, based on an
estimation provided by the Spanish Society of Neonatology
[24]. The mean number of injections per child in the IRIS
studies was 4.1, giving a total acquisition cost of €3,880 per
RSV season. Sensitivity analyses were conducted to assess
the impact on cost-effectiveness of varying vial use.
It was assumed that each complete administration of
palivizumab would take approximately 20 min of a nurse’s
time. The base salary of a nurse who works in the Spanish
National Health Service was obtained from official sources
[25] and inflated to take account of salary increases for
length of service and corresponding social costs (social
security, etc.), providing a cost of € 5.33 for each admin-
istration [17].
Days of RSV hospitalisation
From the IRIS studies, the length of hospital stay due to
RSV was significantly lower for the palivizumab group
than for those who did not receive prophylaxis (6 days vs
8 days; P \ 0.01) [18]. Length of stay (LOS) in the ICU
was derived from another study conducted by the IRIS
Study Group, in which the median length of time spent in
the ICU by preterm children who had not received pro-
phylaxis was 6 days [26]. In both IRIS cohorts, a
considerable proportion of the children required admis-
sion to the ICU, although the difference between groups
was not statistically significant: 13% of those who had
received palivizumab and 20% of controls [18]. There-
fore, it was assumed that the average child would spend
1.2 days in the ICU (20% of 6 days) and that the
remainder of the stay would be spent on a general pae-
diatric ward: 4.8 days for the palivizumab group and
6.8 days for those who did not receive prophylaxis.
Length of hospital stay was varied by ±10% in a sensi-
tivity analysis.
Direct medical costs
Table 3 shows a summary of the unit costs used in the
model for each type of resource. Costs per day in the
paediatric ward, the paediatric ICU, and general ward were
estimated based on information from the previous Spanish
analysis [17]. Costs of outpatient and hospital paediatric
consultations were derived from price lists for public health
services in the Autonomous Community of Madrid [27].
The cost of hospitalisation was varied in a sensitivity
analysis between that of a general paediatric ward (€495/
day) and that of intensive care (€871/day).
Long-term sequelae
Among surviving children, a significant proportion may
develop long-term sequelae (e.g. recurrent wheezing,
asthma) [9, 28]. Data on healthcare resource use related to
hospitalisation for RSV infection were taken from a United
Kingdom study (Table 4) [29]. Neonates born at less than
32 weeks gestational age with a proven RSV admission
made greater use of hospital and community healthcare
resources in the first 2 years of life than a control group
who had been admitted to hospital for non-respiratory
reasons or had not been hospitalised at all.
Table 3 Unit costs
Item Cost/unit
(€)
Reference
Hospitalisation ICU ward 871 [17]
Paediatric ward 495
General ward 495
Other Outpatient visit (hospital) 154 [27]
Primary care visit 49
Primary care visit for
respiratory disease
49
ICU Intensive care unit
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Indirect costs
Indirect costs arise from loss of productive employment
due to premature death. To estimate indirect costs it was
assumed that the proportion of children reaching working
age who are employed, unemployed or not in the labour
market will be similar to the current situation in Spain.
Thus, the proportion of the gross domestic product (GDP;
€ 744,754 million) corresponding to the Spanish population
of both sexes between 16 and 64 years of age (29,370,800
inhabitants) was calculated [30]. This translates to an
average GDP for a person aged 16–64 years of € 25,356,
which was adjusted to € 19,600 after correction for
employment rate (77.3%). which is the value assumed by
the model for each year of life lost [17]. Since it is assumed
that a year in the future is worth less than a year in the
present, the model applies an annual 3% discount rate to
these costs.
Results
Base-case analysis
Costs and clinical outcomes are presented in Table 5.
When the direct costs associated with RSV prophylaxis and
hospitalisation are taken into account, use of palivizumab
results in an additional cost of €6,321 per child. Inclusion
of the costs associated with the long-term consequences of
severe RSV disease (sequelae disease like asthma and
recurrent wheezing) reduces the incremental cost of pali-
vizumab to €3,205. From the societal perspective, includ-
ing both direct and indirect costs, use of palivizumab
results in overall cost savings of €396.
With regard to clinical outcomes, 0.85 fewer undis-
counted life-years are lost with the use of palivizumab than
with no prophylaxis, and 0.33 fewer life-years are lost after
discounting. The inclusion of utilities produces a gain of
0.49 and 1.03 quality-adjusted life-years (QALYs) with
palivizumab, with and without discounting, respectively.
Table 6 shows the cost-effectiveness results. In the base-
case analysis (direct medical costs excluding sequelae
diseases, the use of palivizumab produces an undiscounted
incremental cost-effectiveness ratio (ICER) of €6,142/
QALY, which becomes €12,814/QALY after discounting.
The cost per life-year gained (LYG) is somewhat higher:
€7,475 undiscounted and €18,872 discounted. Inclusion of
the cost of treating sequelae diseases decreases the undis-
counted ICER to €3,114/QALY and the discounted ICER
to €6,498/QALY. When indirect costs are included, pali-
vizumab becomes the dominant strategy from the societal
perspective, as its use results in both clinical benefits and
cost savings versus no prophylaxis.
Scenario analyses
A scenario analysis was performed assuming that there was
no difference in mortality between palivizumab-treated
children and those receiving no prophylaxis, based on the
no prophylaxis rate of mortality from the IRIS studies
(1.39%). The results indicate the high impact of mortality
on the cost-effectiveness outcomes for palivizumab: the
ICERs increase to €32,819/QALY (undiscounted) and
€38,050/QALY (discounted) for the base-case analysis.
Table 7 shows the results of the scenario analysis based
on the 2-year mortality data from the Sampalis study [9].
As in the base-case analysis, the use of palivizumab results
in an additional medical cost of €6,321, which reduces to
€3,205 when the costs associated with sequelae diseases
Table 4 Resource use relating to hospitalisation for RSV infection
[29]
RSV
provena
Controlb Difference
Days in ICU 2.9 0 2.9
Days in paediatric ward 30.7 1.6 29.1
Outpatient visits 11.9 8.6 3.3
GP contacts 16.3 14.6 1.7
Community care contacts 28.2 18.7 9.5
Consultations with GP for
respiratory illness
8.3 5.6 2.7
GP General practitioner
a Neonates born at \ 32 weeks gestational age with at least one
proven RSV hospital admissionbNeonates born at \ 32 weeks ges-
tational age who had been admitted to hospital for non-respiratory
reasons or had not been hospitalised at all
Table 5 Costs and clinical outcomes (base-case analysis)
Palivizumab No
prophylaxis
Difference
Costs
Direct medical costs (€) 7,490 1,169 6,321
Direct medical
costs ? sequelae (€)
8,813 5,608 3,205
Indirect costs (€) 1,034 4,634 -3,601
Total costs
(direct ? indirect) (€)
9,846 10,242 -396
Outcomes
Undiscounted
Life-years lost 0.24 1.09 -0.85
QALYs gained 77.22 76.19 1.03
Discounted
Life-years lost 0.10 0.43 -0.33
QALYs gained 30.20 29.70 0.49
QALY Quality-adjusted life-year
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are included. However, changes in the assumed rate of
mortality have a significant impact on indirect costs. In this
scenario, use of palivizumab leads to cost savings of
€1,828 from a societal perspective. Clinical benefits also
increase relative to the base-case analysis: use of pali-
vizumab results in 1.18 fewer life-years lost (undiscounted)
than with no prophylaxis; 0.47 fewer life-years are lost
after discounting. When utilities are included, the incre-
mental gain achieved with palivizumab prophylaxis is 0.62
and 1.36 QALYs, with and without discounting, respec-
tively. The ICER decreases from €6,142 to €5,108 (no
discounting) and it decreases from €12,814 to €12,279
(discounting).
The median multi-attribute score on the HUI3 did not
differ significantly between the two groups. Thus, a sce-
nario analysis was performed based on a utility of 0.93 (the
utility measured in RSV children in this study) for all
children up to 16 years of age (Table 8).
In this scenario, the life-years lost and economic out-
comes do not change. The use of palivizumab results in
incremental gain of 0.33 QALYs and 0.83 QALYs, with
and without discounting, respectively. The ICER increases
from €6,142 to €7,616 (no discounting) and it increases
from €12,814 to €19,155 (discounting). This scenario also
captures the impact of long-term sequelae, because there is
no long-term difference in utility for patients with and
without long-term sequelae.
Sensitivity analyses
Figure 2 shows the results of univariate sensitivity
analyses, which were performed on discounting, vials,
hospitalisation costs, LOS. These results show that the
cost-effectiveness outcome for palivizumab is sensitive to
the rate of discounting applied to effectiveness measures.
When discounting is applied only to costs, variations in the
rate used have no effect as only short-term costs are
included in the base-case analysis. However, model out-
comes are very sensitive to changes in the discount rate
when this is also applied to effectiveness. The model out-
comes are also sensitive to assumptions regarding vial use.
In the base-case analysis, it was assumed that a 100 mg
vial would be used for the majority (95%) of administra-
tions of palivizumab. When it is assumed that only 50 mg
vials are used, the ICER falls from €12,814/QALY to
€6,768/QALY.
Figure 3 shows the cost-effectiveness acceptability
curves for palivizumab versus no prophylaxis. This figure
was based on a probabilistic sensitivity analysis with
effectiveness discounted, using beta distributions for hos-
pitalisation probabilities, mortality and vial use, and a
normal distribution for hospital LOS and resource use for
recurrent wheezing, respectively. The cost-effectiveness
acceptability curve illustrates that there is close to 100%
Table 6 Incremental cost-effectiveness ratios (ICER)
Undiscounted
ICER
Discounted
ICER
Base-case analysis LYG €7,475 €18,872
QALY €6,142 €12,814
Direct costs ? sequelae diseases LYG €3,791 €9,570
QALY €3,114 €6,498
Total costs LYG Dominant Dominant
QALY Dominant Dominant
LYG life-year gained
Table 7 Scenario analysis based on alternative 2-year mortality data
Palivizumab No
prophylaxis
Difference
Costs
Direct medical costs (€) 7,490 1,169 6,321
Direct medical
costs ? sequelae (€)
8,813 5,608 3,205
Indirect costs (€) 2,138 7,171 -5,033
Total costs
(direct ? indirect) (€)
10,950 12,778 -1,828
Outcomes
No discounting
Life-years lost 0.50 1.68 -1.18
QALYs gained 76.96 75.60 1.36
Discounting
Life-years lost 0.20 0.67 -0.47
QALYs gained 30.10 29.48 0.62
Table 8 Scenario analysis based on alternative 3-year mortality data
Palivizumab No
prophylaxis
Difference
Costs
Direct medical costs (€) 7,490 1,169 6,321
Direct medical
costs ? sequelae (€)
8,813 5,608 3,205
Indirect costs (€) 2,138 7,171 -5,033
Total costs
(direct ? indirect) (€)
10,950 12,778 -1,828
Outcomes
No discounting
Life-years lost 0.24 1.09 -0.85
QALYs gained 77.00 76.17 0.83
Discounting
Life-years lost 0.10 0.43 -0.33
QALYs gained 30.01 29.69 0.33
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probability that the ICER of palivizumab will be less than
€30,000/QALY—the threshold below which interventions
are generally considered to be cost effective [31].
Discussion and conclusions
The objective of the current analysis was to confirm the
cost-effectiveness of palivizumab prophylaxis in Spain,
originally calculated based on international trial data,
through incorporation of country-specific observational
data. The original core cost-effectiveness model calculated
a discounted ICER of €13,849/QALY, taking into account
the direct medical costs associated with RSV prophylaxis
and hospitalisation [17]. Even in the least favourable sce-
nario, the ICER was lower than the €30,000/QALY
threshold. The comparable ICER produced by the new
model, incorporating data from the IRIS Study Group, was
€12,814/QALY. These results show that the use of Spanish
observational data not only increases the external validity
of the results, but also yields a slightly more favourable
cost-effectiveness outcome than the use of international
clinical trial data.
Improvements in the cost-effectiveness outcome may be
explained by differences in the rates of hospitalisation used
in the two models. The original cost-effectiveness model
was based on data from the international IMpact trial,
which was conducted in 139 centres in the United States,
United Kingdom and Canada. The average rate of hospi-
talisation in the palivizumab arm was 4.8% compared with
10.6% in the no prophylaxis arm: a 55% reduction in rel-
ative risk [6]. The revised model is based on Spanish
hospitalisation rates from the IRIS studies. Use of pali-
vizumab resulted in a 70% overall reduction in the rate of
RSV hospitalisation in Spain, from 13.25% in the control
cohort to 3.95% in those infants receiving palivizumab
[18]. The 13.25% RSV hospitalisation in the control cohort
also corresponds with the incidence of RSV hospitalisation,
which was 13.5% in the placebo group in the PREVENT
Study [5].
The current cost-effectiveness model eliminated some of
the limitations of the previous cost-effectiveness model.
The impact of palivizumab was extended beyond a single
RSV season and the hospitalisation rates were based on
local Spanish data corresponding with treatment practise in
Spain, whereas the previous model was based on hospi-
talisation rates derived from an international clinical trial
(IMpact). The results of the current model show that the
outcomes of the model are rather robust, as the ICER of the
current model (€12,814/QALY) is close to the initial ICER
of €13,849/QALY. Therefore the current analysis is a
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validation of the initial cost-effectiveness results from the
previous model.
The analysis also shows that the cost-effectiveness
outcomes are sensitive to the assumed rate of mortality. If
it is assumed that palivizumab prophylaxis has no impact
on the rate of mortality, as in the scenario analysis in which
the no prophylaxis rate of mortality was employed for both
cohorts of at-risk infants, cost-effectiveness outcomes
become significantly less favourable than in the base-case
analysis (€38,050/QALY versus €12,814, respectively).
Conversely, incorporation of the 2-year mortality data from
the Sampalis study results in more favourable outcomes for
palivizumab compared with the base-case, due to improved
clinical outcomes and greater indirect cost savings.
The results presented here confirm that palivizumab
provides a cost-effective method of prophylaxis against
severe RSV disease among preterm infants in Spain. Use of
Spanish observational data further increases the validity of
the results for the Spanish healthcare setting in 2006 and
confirms the conclusion of the previous cost-effectiveness
study.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
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